Obecetrapib CETP inhibitor LDL lowering

Thanks for asking—totally reasonable to be curious here. Obicetrapib is a CETP inhibitor (same drug class as anacetrapib/evacetrapib), aimed at lowering LDL and ApoB. It’s still investigational in the US and not available for routine prescribing. Phase 2/early phase 3 studies showed substantial LDL and ApoB reductions on top of statins, and a large cardiovascular outcomes trial (BROOKLYN/ROSE/TRIAD programs; key one is PREVAIL) is ongoing. Prior CETP drugs had mixed or negative outcome results despite lipid changes, so regulators will wait for clear event‑reduction data. For now, proven options to drive risk down remain statins, ezetimibe, PCSK9 inhibitors, and lifestyle, especially if LDL/ApoB targets aren’t met.